Latest From Alector Inc.
The Dementia Discovery Fund is backing the UCL spin-off's efforts to develop therapies that modulate astrocyte function.
A group of early-stage investigational cancer, myelofibrosis and immune-oncology products have been tagged by AbbVie as potential therapies of interest longer term.
There have been eight US biopharma IPOs in 2019, but only three are trading above their launch price – a big change from just three days ago.
Public Company Edition: Four more IPOs in the US bring the year's total to seven – all in February. Also, Agenus launched its digital security offering, MacroGenics leads recent follow-on offerings and four companies reveal new job cuts.
Drug Discovery Tools
- Drug Discovery Tools
- Therapeutic Areas
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- Alector Inc.
- Senior Management
Arnon Rosenthal, PhD, Pres. & CEO
Robert Paul, MD, PhD, CMO
Robert King, PhD, Chief Dev. Officer
Sabah Oney, PhD, CBO
Calvin Yu, Head, Fin.
- Contact Info
Phone: (415) 231-5660
151 Oyster Point Blvd.
South San Francisco, CA 94080
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.